[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@dr_yakupergun Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1008888613.png) @dr_yakupergun Yakup Ergün

Yakup Ergün posts on X about delta, os, rates, longterm the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1008888613/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1008888613/c:line/m:interactions.svg)

- X Week XXXXXX +95%
- X Month XXXXXXX +1,019%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +174%

### Mentions: XX [#](/creator/twitter::1008888613/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1008888613/c:line/m:posts_active.svg)

- X Week XX +115%
- X Month XX +280%
- X Months XXX +79%
- X Year XXX +227%

### Followers: XXXXX [#](/creator/twitter::1008888613/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1008888613/c:line/m:followers.svg)

- X Week XXXXX +3.70%
- X Month XXXXX +6.20%
- X Months XXXXX +29%
- X Year XXXXX +79%

### CreatorRank: XXXXXXX [#](/creator/twitter::1008888613/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1008888613/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1008888613/influence)
---

**Social category influence**
[travel destinations](/list/travel-destinations)  XXX% [currencies](/list/currencies)  XXX%

**Social topic influence**
[delta](/topic/delta) 6.9%, [os](/topic/os) #713, [rates](/topic/rates) #666, [longterm](/topic/longterm) 6.9%, [matterhorn](/topic/matterhorn) #50, [pts](/topic/pts) #597, [ct](/topic/ct) 3.45%, [1l](/topic/1l) #6

**Top accounts mentioned or mentioned by**
[@ozdogan_md](/creator/undefined) [@suyogcancer](/creator/undefined) [@oncbrothers](/creator/undefined) [@carinecccc](/creator/undefined) [@samuelxstevens](/creator/undefined) [@oscartahuahua](/creator/undefined) [@sankardummy2s](/creator/undefined) [@dr_elvinaa](/creator/undefined) [@larvol](/creator/undefined) [@medwatchkate](/creator/undefined)
### Top Social Posts [#](/creator/twitter::1008888613/posts)
---
Top posts by engagements in the last XX hours

"#ESMO25 XX mg pembrolizumab every X weeks In the neoadjuvant phase of KEYNOTE-522 a similar increase in pCR was achieved with only XX% of that dose What is the optimal dose for immunotherapy agents"  
[X Link](https://x.com/dr_yakupergun/status/1979163315134775355) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-17T12:31Z 6174 followers, 31.5K engagements


"#ESMO25 DESTINY-Breast11: First results Neoadjuvant T-DXd-THP vs ddAC-THP ✅pCR: XXXX vs XXXX % ( +11.2 %) Benefit in both HR+ (61 vs XX %) and HR (83 vs XX %) EFS trend: HR XXXX Grade X AEs: XX vs XX %; ILD XXX % LV dysf. XXX % New SoC"  
[X Link](https://x.com/dr_yakupergun/status/1977592051240988692) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-13T04:27Z 6174 followers, 17.7K engagements


"#ESMO25 TROPION-Breast02 (Dato-DXd vs CT 1L PD-(L)1ineligible mTNBC) Dato-DXd markedly improved outcomes vs chemo mPFS XXXX vs XXX mo (HR 0.57) ORR XX% vs XX% with no grade X TRAEs and a confirmed OS benefit. I think Dato-DXd is clearly ahead of SG👏👏👏"  
[X Link](https://x.com/dr_yakupergun/status/1979815326360744120) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-19T07:42Z 6174 followers, 7312 engagements


"#ESMO25 BEGONIA: Dato-DXd + Durvalumab as 1L in a/mTNBC 🔹 All-comer cohort: ORR XX% mDoR XXXX mo mPFS XX mo 🔹 PD-L1high cohort: ORR XX% 💬 In line with ASCENT-03/04 and TROPION-Breast02 supporting chemo-free ADC+/-IO as a potential new 1L strategy in mTNBC"  
[X Link](https://x.com/dr_yakupergun/status/1977764147552010560) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-13T15:51Z 6174 followers, 8871 engagements


"Ask any breast oncologist today and theyll tell you they prefer anthracycline-free regimens in HER2-positive breast cancer and that anthracyclines dont improve response rates. So how did we accept a control arm containing anthracyclines in the DESTINY-Breast11 trial which began in October 2021 We cant simply call this a sponsor-driven choice. Its the physicians who persuade patients to enroll physicians who also receive payment for every screening and treatment visit. Lets be honest: how do you justify to your patients a control arm that doesnt reflect your own real-world practice Im open to"  
[X Link](https://x.com/dr_yakupergun/status/1979628543413035440) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-18T19:19Z 6174 followers, 18.9K engagements


"#ESMO25 PAULIEN trial: 🔍 First randomized head-to-head trial of 1L pembro chemo in PD-L1 XX% NSCLC 🔹 Stopped early for futility no added benefit from chemo 💬 Response by tumor burden metastatic sites and molecular subtypes remains unclear"  
[X Link](https://x.com/dr_yakupergun/status/1980239583909695645) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-20T11:48Z 6174 followers, 16.6K engagements


"To be honest this is not a neoadjuvant regimen Im particularly satisfied with. We already have effective anthracycline-free options that are shorter in duration (such as THP or TCbHP). The EFS trend is indeed notable it seems worth waiting a bit longer for more mature results. It doesnt feel very reasonable to give such a potent agent for only four cycles in the neoadjuvant setting and then stop. Well soon see the results of DB-05 as well; perhaps using it in the adjuvant phase for patients with residual disease would make more sense. This congress will reveal many new data but it will also"  
[X Link](https://x.com/dr_yakupergun/status/1977615827072348574) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-13T06:02Z 6164 followers, XXX engagements


"#ESMO25 ALINA: Adjuvant alectinib vs chemo in resected ALK+ NSCLC 🔹 4-year follow-up 🔹 DFS: HR 0.350.36 4y rate XX% vs XX% 🔹 CNS-DFS: HR XXXX 🔹 OS immature 💬 Long-term data confirm adjuvant alectinib as standard of care in resected ALK+ NSCLC"  
[X Link](https://x.com/dr_yakupergun/status/1978054899012116809) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-14T11:06Z 6152 followers, 2443 engagements


"#ESMO25 NATALEE: 5-Year Outcomes ✅5-yr iDFS: XXXX% vs XXXX% (HR 0.72)(+4.5%) ✅DRFS: HR XXXX 🔹OS trend: HR XXXX 💬 Continued iDFS and DRFS benefit with a positive emerging OS trend in favor of adjuvant ribociclib + NSAI"  
[X Link](https://x.com/dr_yakupergun/status/1979044611340296388) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-17T04:39Z 6149 followers, 6864 engagements


"#ESMO25 MATTERHORN: OS Results ✅OS: HR XXXX (0.630.96) 💬OS benefit observed independent of PD-L1 status however PD-L1negative pts represented only XX % of the cohort interpret cautiously. 📌MATTERHORN confirms FLOT + Durva as the peri-operative SoC in G/GEJ cancer"  
[X Link](https://x.com/dr_yakupergun/status/1979158059977998527) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-17T12:10Z 6164 followers, 1551 engagements


"#ESMO25 HRS-4642 (KRAS G12D inhibitor phase I) No DLTs; grade X TRAEs in 24%. NSCLC (n=38): ORR XXXX% DCR XXXX% mPFS XXX mo PDAC (n=24): ORR XXXX% DCR XXXX% mPFS XXX mo"  
[X Link](https://x.com/dr_yakupergun/status/1979896385668571439) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-19T13:04Z 6141 followers, 1010 engagements


"#ESMO25 Presidential Session X is about to start heres whats coming: HARMONi-6: Ivonescimab + chemo vs tislelizumab OptiTROP-Lung04: Sac-TMT vs chemo in EGFR NSCLC PSMAddition: Lu-PSMA-617 + ADT + ARPI Disitamab vedotin + toripalimab: vs chemo in 1L HER2-expressing urothelial cancer And yes all positive of course 👍"  
[X Link](https://x.com/dr_yakupergun/status/1979913006717767952) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-19T14:10Z 6146 followers, XXX engagements


"#ESMO25 Low-dose pembrolizumab in TNBC 📌 Phase II RCT: neoadj ddAC paclitaxel pembro XX mg q6w X 🔹 pCR: XXXX % vs XXXX % (+13.3 %; p = 0.047) 💬 Despite 10-fold lower IO exposure the pCR delta (13%) mirrors KN-522. The lower pCR in the control arm likely reflects the absence of carboplatin underscoring the contribution of platinum to baseline efficacy in KN-522. May represent a feasible low-cost IO option in resource-limited settings. 🧩 Diff KN-522: Chemo: ddAC paclitaxel (no carbo) vs paclitaxel + carboplatin AC/EC Pembro dose: XX mg q6w X vs XXX mg q3w X pCR gain: +13.3 % vs +13.6 %"  
[X Link](https://x.com/dr_yakupergun/status/1979063838898065535) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-17T05:56Z 6174 followers, 30.6K engagements


"#ESMO25 DESTINY-Breast11-Positive✅ but Current standard: X THP or TCbHP already short & anthracycline-free. pCR XX% is notable but if residual disease remains then what Will we give T-DM1 which is weaker than T-DXd Or extrapolate from DB-05 and use adjuvant T-DXd as well Maybe neratinib OR tucatinib Many open questions"  
[X Link](https://x.com/dr_yakupergun/status/1979557468414828872) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-18T14:37Z 6174 followers, 11K engagements


"#ESMO25 HRS-7058 (KRAS G12C inhibitor) Phase I (n=81; NSCLC XX CRC XX PDAC 4) Well tolerated up to XXX mg BID no DLTs mainly grade XX diarrhea. KRAS G12Cnave NSCLC: ORR XXXX% DCR XXXX% Pre-treated NSCLC: ORR XXXX% DCR XXXX% CRC: ORR XXXX% DCR XXXX% PDAC: ORR XX% DCR 100%"  
[X Link](https://x.com/dr_yakupergun/status/1979895130497622476) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-19T12:59Z 6174 followers, XXX engagements


"#ESMO25 SONIA trial: OS uptade 🔹OS: XXXX mo vs XXXX mo 💬 OS similar overall; trend favoring 1L use in premenopausal patients. Given the expanding landscape of molecularly guided therapies deferring CDK4/6 inhibitors to later lines seems less likely in real-world practice (IMO)"  
[X Link](https://x.com/dr_yakupergun/status/1980201053522977110) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-20T09:14Z 6169 followers, 7266 engagements


"#ESMO25 BEGONIA update : Dato-DXd + Durvalumab in 1L a/mTNBC 🔹 All-comer cohort: ORR XX% mDoR XXXX mo mPFS XX mo 🔹 PD-L1high cohort: ORR XX% 💬 Alongside ASCENT-04/03 and TROPION-Breast02 supports ADCIO as a rising 1L option in TNBC"  
[X Link](https://x.com/dr_yakupergun/status/1980201416800313497) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-20T09:16Z 6171 followers, 4627 engagements


"#ESMO25 GEICAM El lamo (n=22989) Anthracycline-based chemotherapy significantly increased the risk of contralateral breast cancer and second primary malignancies (IRR 1.46; p=0.039). 💬 Real-world data remind us once again: long-term toxicity cannot be ignored"  
[X Link](https://x.com/dr_yakupergun/status/1980242819634659448) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-20T12:00Z 6174 followers, 4995 engagements


"In the MATTERHORN trial PD-L1negative patients represented only about XX% of the total population making any conclusions extremely difficult. Based on extrapolation from metastatic-stage studies where IO showed no benefit in PD-L1negative tumors it is likely that immunotherapy would also be ineffective in the perioperative setting although we currently lack data to confirm this (HR XXXX in both groups with wide confidence intervals due to small numbers). Until proven otherwise I would recommend neoadjuvant durvalumab for all patients who can access the drug regardless of PD-L1 status; however"  
[X Link](https://x.com/dr_yakupergun/status/1981074760202158197) [@dr_yakupergun](/creator/x/dr_yakupergun) 2025-10-22T19:06Z 6174 followers, XXX engagements